Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers

Journal of Clinical Pharmacology

Volumn 45, Issue 2, 2005, Pages 211-218

  La Porte, Charles ^a   Verweij Van Wissen, C ^a   Van Ewijk, N ^a   Aarnoutse, R ^a   Koopmans, P ^a   Reiss, P ^b   Stek Jr , M ^c   Hekster, Y ^a   Burger, D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Didanosine; Drug interactions; Highly active antiretroviral therapy (HAART); Indinavir; Pharmacokinetics; Ritonavir

Indexed keywords

DIDANOSINE; INDINAVIR; RITONAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG DOSE REGIMEN; DRUG FORMULATION; ENTERIC COATED TABLET; FEMALE; FOOD DRUG INTERACTION; FOOD INTAKE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CAPSULES; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DIDANOSINE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; FOOD-DRUG INTERACTIONS; HALF-LIFE; HUMAN EXPERIMENTATION; HUMANS; INDINAVIR; MALE; REPRODUCIBILITY OF RESULTS; RITONAVIR; THERAPEUTIC EQUIVALENCY;

EID: 16844379887     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004271063     Document Type: Article

References (18)

1. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
2. Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS. 1997;11:1665-1670.
3. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis. 2001;33:865-872.
4. Crixivan [product information]. Whitehouse Station, NJ: Merck & Co; 2002.
5. Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers. Antimicrob Agents Chemother. 1998;42:2784-2791.
6. van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS. 1999;13:F95-F99.
7. Burger DM, Hugen PW, Aarnoutse RE, et al. A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr. 2001;26:218-224.
8. Hugen PW, Burger DM, ter Hofstede HJ, et al. Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr. 2000;25:236-245.
9. Burger DM, Aarnoutse RE, Dieleman JP, et al. A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleosicte reverse transcriptase inhibitors (PIPO study). Antivir Ther. 2003;8:455-461.
10. Videx EC [summary of product characteristics]. Woerden, the Netherlands: Bristol-Myers Squibb BV; 2003.
11. Hugen PW, Verweij-van Wissen CP, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Simultaneous determination of the HIV-protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 1999;727:139-149.
12. Aarnoutse RE, Grintjes KJ, Telgt DS, et al. The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers. Clin Pharmacol Ther. 2002;71:57-67.
13. Williams RL, Chen ML, Hauck WW. Equivalence approaches. Clin Pharmacol Ther. 2002;72:229-237.
14. Dieleman JP, Gyssens IC, van der Ende ME, de Marie S, Burger DM. Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients. AIDS. 1999;13:473-478.
15. Saah A, Winchell G, Seniuk M, Mehrotra D, Deutsch P. Multiple-dose pharmacokinetics and tolerability of indinavir-ritonavir combinations in healthy volunteers [abstract 362]. Paper presented at: 6th Conference on Retroviruses and Opportunistic Infections; January-February 1999; Chicago.
16. Damle BD, Mummaneni V, Kaul S, Rnupp C. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin. Antimicrob Agents Chemother. 2002;46:385-391.
17. Damle BD, Yan JH, Behr D, et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol. 2002;42:419-427.
18. Damle BD, Kaul S, Behr D, Knupp C. Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects. J Clin Pharmacol. 2002;42:791-797.